- Opus Genetics will hold its annual stockholders meeting virtually on April 20, 2026.
- Shareholders will vote on the election of nine director nominees to the board.
- Items for advisory votes include the ratification of Ernst & Young as independent public accounting firm and approval of named executive officer compensation.
- Another proposal seeks approval of an amendment to increase authorized common shares to 250,000,000 from 125,000,000.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-010757), on March 23, 2026, and is solely responsible for the information contained therein.